Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers
Conflicting results have been reported regarding the prevalence of screen-detected human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas and non-screen detected HER2-positive breast carcinomas. To address this issue, we evaluated the prevalence of HER2-positive breast carcinomas...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/6/1578 |
| _version_ | 1797565243052785664 |
|---|---|
| author | M. Ángeles López-García Irene Carretero-Barrio Belén Pérez-Míes Miguel Chiva Carolina Castilla Begoña Vieites José Palacios |
| author_facet | M. Ángeles López-García Irene Carretero-Barrio Belén Pérez-Míes Miguel Chiva Carolina Castilla Begoña Vieites José Palacios |
| author_sort | M. Ángeles López-García |
| collection | DOAJ |
| description | Conflicting results have been reported regarding the prevalence of screen-detected human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas and non-screen detected HER2-positive breast carcinomas. To address this issue, we evaluated the prevalence of HER2-positive breast carcinomas in two independent regional screening programs in Spain. The clinicopathologic and immunohistochemical characteristics of 479 (306 and 173) screen-detected breast carcinomas and 819 (479 and 340) non-screen-detected breast carcinomas diagnosed in women between 50 and 69-year-olds were compared. The prevalence of HER2-positive breast carcinomas was 8.8% and 6.4% in the two series of screen-detected tumors, compared with 16.4% and 13% in non-screen-detected carcinomas. These differences were statistically significant. This lower prevalence of HER2-positive in-screen-detected breast carcinomas was observed in both hormone receptor positive (luminal HER2) and hormone-receptor-negative (HER2 enriched) tumors. In addition, a lower prevalence of triple-negative and a higher prevalence of luminal-A breast carcinomas was observed in screen-detected tumors. Moreover, a literature review pointed out important differences in subrogate molecular types in screen-detected breast carcinomas among reported series, mainly due to study design, technical issues and racial differences. |
| first_indexed | 2024-03-10T19:09:22Z |
| format | Article |
| id | doaj.art-9bc9e313469b4d67a7969fcbfd3698aa |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:09:22Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9bc9e313469b4d67a7969fcbfd3698aa2023-11-20T03:55:04ZengMDPI AGCancers2072-66942020-06-01126157810.3390/cancers12061578Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast CancersM. Ángeles López-García0Irene Carretero-Barrio1Belén Pérez-Míes2Miguel Chiva3Carolina Castilla4Begoña Vieites5José Palacios6Unidad de Anatomía Patológica, Hospital Universitario Virgen del Rocío, 41013 Sevilla, SpainPathology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, SpainBreast Pathology Unit, Hospital Universitario Ramón y Cajal, 28034 Madrid, SpainNodo Biobanco Hospital Universitario Virgen del Rocío—Instituto de Biomedicina de Sevilla, Biobanco del SSPA, Unidad de Anatomía Patológica, Hospital Universitario Virgen del Rocío, 41013 Sevilla, SpainUnidad de Anatomía Patológica, Hospital Universitario Virgen del Rocío, 41013 Sevilla, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, SpainConflicting results have been reported regarding the prevalence of screen-detected human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas and non-screen detected HER2-positive breast carcinomas. To address this issue, we evaluated the prevalence of HER2-positive breast carcinomas in two independent regional screening programs in Spain. The clinicopathologic and immunohistochemical characteristics of 479 (306 and 173) screen-detected breast carcinomas and 819 (479 and 340) non-screen-detected breast carcinomas diagnosed in women between 50 and 69-year-olds were compared. The prevalence of HER2-positive breast carcinomas was 8.8% and 6.4% in the two series of screen-detected tumors, compared with 16.4% and 13% in non-screen-detected carcinomas. These differences were statistically significant. This lower prevalence of HER2-positive in-screen-detected breast carcinomas was observed in both hormone receptor positive (luminal HER2) and hormone-receptor-negative (HER2 enriched) tumors. In addition, a lower prevalence of triple-negative and a higher prevalence of luminal-A breast carcinomas was observed in screen-detected tumors. Moreover, a literature review pointed out important differences in subrogate molecular types in screen-detected breast carcinomas among reported series, mainly due to study design, technical issues and racial differences.https://www.mdpi.com/2072-6694/12/6/1578breast cancerscreeningHER2estrogen receptorprogesterone receptortriple negative |
| spellingShingle | M. Ángeles López-García Irene Carretero-Barrio Belén Pérez-Míes Miguel Chiva Carolina Castilla Begoña Vieites José Palacios Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers Cancers breast cancer screening HER2 estrogen receptor progesterone receptor triple negative |
| title | Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers |
| title_full | Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers |
| title_fullStr | Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers |
| title_full_unstemmed | Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers |
| title_short | Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers |
| title_sort | low prevalence of her2 positive breast carcinomas among screening detected breast cancers |
| topic | breast cancer screening HER2 estrogen receptor progesterone receptor triple negative |
| url | https://www.mdpi.com/2072-6694/12/6/1578 |
| work_keys_str_mv | AT mangeleslopezgarcia lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers AT irenecarreterobarrio lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers AT belenperezmies lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers AT miguelchiva lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers AT carolinacastilla lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers AT begonavieites lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers AT josepalacios lowprevalenceofher2positivebreastcarcinomasamongscreeningdetectedbreastcancers |